The group’s principle activity is to in-license promising pharmaceutical and medical device technologies in the late preclinical development phase and conducts proof-of-principle clinical studies on a virtual basis for eventual corporate partnership and commercialization. The group’s products include MRX-1024, and MRX-1024. The group operates from United States.
